Navigation Links
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
Date:9/9/2008

LAS VEGAS, Sept. 9 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) today announces that its first US site is open for patient enrollment for its Phase II clinical trial for the treatment of severe coronary heart disease. In the coming weeks, CVBT anticipates announcing additional sites as they open for enrollment. For current details about the clinical sites participating in CVBT's Phase II heart trial, please visit http://www.cvbt.com.

In this Phase II trial, CVBT's drug candidate containing human Fibroblast Growth Factor-1 (FGF-1), will be injected into patients' hearts, stimulating a healing process called angiogenesis. The drug will be delivered using the NOGA(R) XP Cardiac Navigation system and the MyoStar(TM) injection catheter.

Subjects must be between 25 and 75 years of age with at least a 3 month history of chronic stable angina triggered by physical exertion and must have a Canadian Cardiovascular Society (CCS) anginal classification III or IV while receiving optimal medical therapy. Their treating cardiologist will have determined that they are generally not suitable for interventional therapy or bypass surgery.

"Developing a clinical trial protocol such as ours takes an extraordinary amount of time and effort, and I am pleased to finally open our Phase II heart trial for patient screening," said Daniel C. Montano, CVBT's President and CEO. "I expect additional investigators at other hospitals to begin screening patients in the coming weeks. Our target is 30 hospitals for this international Phase II heart trial."

About CardioVascular BioTherapeutics

CVBT (OTC Bulletin Board: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the com
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genomic Health Announces Data Supporting Use of Oncotype DX(R) to Accurately Assess HER2 Gene Expression in Breast Cancer Patients
2. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
3. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
4. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
5. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
6. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
7. Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
8. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
9. Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments
10. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015  Thoratec Corporation (NASDAQ: THOR ), a world ... restore failing hearts, announced today that Marta Antonucci ... International. This new Europe -based ... North America , including Europe ... Latin America , and reports directly to the Chief ...
(Date:5/1/2015)... 2015  Legendary actor and director Danny Glover ... campaign designed to educate and encourage patients with neurologic ... Affect (PBA) and to speak with their physician. The ... the ability to cry and laugh on cue and ... by people living with PBA episodes. While ...
(Date:5/1/2015)... CITY, Calif. , May 1, 2015  AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that Timothy E. Morris , chief financial ...  Details of the events are as follows: ... May 5 Location:  The Omni Berkshire Place, ...
Breaking Medicine Technology:Thoratec Announces Addition To Senior Management Team 2Thoratec Announces Addition To Senior Management Team 3Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 2Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA), a Little Known but Widespread Neurologic Condition 3AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2
... proud to announce its conference keynote speakers include: Centers ... CBS Evening News Anchor Katie Couric; U.S. ... U.S. Secretary of Commerce Gary Locke. Each will address ... leaders in Washington, D.C. October 18-20 during AdvaMed ...
... Arlington Medical Resources (AMR), a provider of premier ... finds that more than half of all European inpatients ... Sanofi-Aventis,s Clexane (marketed as Lovenox in the U.S. and ... The European Hospital Anticoagulant Market Guide is a ...
Cached Medicine Technology:AdvaMed 2010 Keynote Speakers Announced 2AdvaMed 2010 Keynote Speakers Announced 3European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane 2
(Date:5/2/2015)... 2015 Vancouver fencing company, QS Fencing, has ... advice to prospective clients related to their questions on railings ... railings around their decks and patios. While that seems like ... up once the person rolls up their sleeve to start ... railing in finding a gate that matches it. , Instead ...
(Date:5/2/2015)... 2015 It’s a pattern that won’t ... strikes anywhere on this planet, cyber scammers will immediately ... compassion for their own personal gain. And on ... Team) issued an alert titled “Nepal Earthquake Disaster ... citing the earthquake in Nepal. The scam emails may ...
(Date:5/2/2015)... Ohio (PRWEB) May 02, 2015 On ... Liverpool City Hospital (ELCH) gathered to celebrate improvements in ... River Valley Health Partners (RVHP), had zero acquired ventilator ... urinary catheter associated infections. ELCH was also recently named ... The management team at ELCH credited the teamwork of ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Caicos Islands, BWI (PRWEB) May 02, 2015 ... website! It is http://www.thevenetiangracebay.com , and it ... it incorporates the stunning white and attractive turquoise hues ... study of Google, sixty seven percent of leisure travelers ... study showed that smartphones were used in the planning ...
Breaking Medicine News(10 mins):Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 2Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 3Health News:Cyber Aftershocks from Nepal’s Earthquake Can Cripple Businesses Right Here at Home 4Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... fibrillation stop taking anti-clotting drugs, their stroke risk goes ... about the same whether they are taking warfarin or ... fibrillation is an abnormal heart rhythm in which the ...
... There is an association between the rs1051730-rs16969968 genotype and ... cancer risk is largely, if not entirely, mediated by ... April 25 in the Journal of the National ... to be associated with heaviness of smoking, lung cancer ...
... News) -- Heroin addicts often have an increased sensitivity ... the course of treatment with methadone or other opioids, ... California-Los Angeles sought to determine how increased sensitivity to ... addict moves from drug abuse to stabilization and eventually ...
... of care collaboration to diagnosis, treat and follow ... which require rapid, resource-intensive care and confer a ... April 24 in Circulation . Specifically, cardiovascular ... non-STEMI/unstable angina, out-of-hospital cardiac arrest (OHCA), acute aortic ...
... Mass. (April 25, 2012) Developmental biologists at Tufts ... organisms recognize and repair head and facial abnormalities. ... mechanism has been reported for the face and the ... has been rigorously analyzed through mathematical modeling. ...
... of ways to treat a heart attack CPR, aspirin, ... a new candidate: Intense light. "The study ... the risk of having a heart attack or suffering damage ... of anesthesiology, cardiology, and cell and developmental biology at ...
Cached Medicine News:Health News:Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat 2Health News:Genetic variants, tobacco exposure and lung cancer risk 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2Health News:Facial defects shown to self-repair 2Health News:Facial defects shown to self-repair 3Health News:Intense light prevents, treats heart attacks 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: